TrakCel Extends Eco-System to Integrate Lead Product OCELLOS with Additional Cell and Gene Therapy Platforms and Systems
Cardiff, UK, April 18, 2023 – TrakCel, the leading supplier of cellular orchestration solutions for clinical trials and commercial therapies to the cell and gene therapy (CGT) industry, today announces its latest update to OCELLOS, its lead advanced therapy orchestration product, via additions to the TrakCel partner ecosystem.
The TrakCel ecosystem integrates the widest range of partners across the cell and gene therapy supply chain. The TrakCel partners include couriers, CDMOs, clinical data system developers, patient hub services companies, and CGT labelling systems. This integration extends the ecosystem to 12 integrated partners. A further four TrakCel partners are progressing through proof-of-concept integrations that are scheduled to be completed by the end of 2023.
The latest update has integrations with decentralized clinical trial platforms and Enterprise Resource Planning (ERP) systems available, paving the way for the cell and gene therapy developers to work with these partners or integrate their own trial platforms or ERP systems with OCELLOS. The integration means that TrakCel’s OCELLOS is able to import, display and report on the data from both the clinical trial platform and ERP system, as well as send data back to those systems.
“TrakCel has worked hard to select the right integration partners to develop a real eco-system that can serve the needs of the entire cell and gene therapy sector. This enables a true team of supply chain partners, from couriers, manufacturing users, Patient Case Managers and others across the supply chain that can share information in real time and be automatically informed through TrakCel’s OCELLOS when there are changes. This will have a transformative effect on the CGT supply chain,” said Chris Came, VP Global Alliances & Client Services, TrakCel.
“These latest integrations will enable TrakCel to communicate with ERP systems to send and receive updates around key manufacturing milestones as they are met and ensure complete visibility across the wider supply and value chains, and decentralized clinical trial platforms to further safeguard the chain of identity and similar patient identifiers. This will be as important a development to the delivery of therapies to patients as the discovery of the therapies themselves.”
TrakCel has ensured that the automated cross-platform transfer of data removes the need for manual transfer of information and files, reducing errors and management time. This will be vital for the cell and gene therapy sector, where real time updates and on demand data is critical to meeting process criteria and optimizing time to treatment. Users receive automated notifications if a process is outside of stated parameters, or there is an action or development that requires urgent attention.
TrakCel is the market leading developer of integrated cell orchestration solutions. TrakCel has specifically designed these solutions to manage the international autologous and allogeneic cell, gene and immunotherapy value and supply chains. Its platform has evolved in collaboration with, and is increasingly adopted by, leading companies in the cell, gene and immunotherapy industries.
TrakCel’s solutions enable real-time control for all organizations working across the entire therapeutic value chain. This control includes patient eligibility (commercial) and enrolment, sample collection, manufacturing and treatment delivery. The TrakCel platform accelerates global scale-up and scale-out of cell and gene therapy products, increasing efficiency and decreasing complexity, while safe-guarding Chain of Custody and Chain of Identity with a full electronic audit trail for administration compliance and traceability. TrakCel was founded in 2012. It’s headquartered in Cardiff, UK with US offices in California. https://trakcel.com.
For more information:
Neil Hunter / Michelle Boxall
Tel: +44 (0) 20 8943 4685
Article by TrakCel Marketing Team - 18 Apr 2023